Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Adverum Biotechnologies, Inc. (ADVM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.0600-0.0200 (-1.85%)
At close: 04:00PM EDT
1.0900 +0.03 (+2.83%)
After hours: 05:41PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.0800
Open1.0700
Bid1.0500 x 1000
Ask1.0900 x 3200
Day's Range1.0150 - 1.1100
52 Week Range0.7950 - 3.7910
Volume10,642,101
Avg. Volume1,178,753
Market Cap104.041M
Beta (5Y Monthly)1.21
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Benzinga

    Adverum's Data at ASGCT Further Supports Phase 2 Development Plans For Wet-AMD Gene Therapy

    Adverum Biotechnologies Inc (NASDAQ: ADVM) has shared new data from the ADVM-022 development program in wet age-related macular degeneration (wet AMD). The data were presented at the American Society of Gene and Cell Therapy (ASGCT) 2022 Annual Meeting. It exhibited results of the non-human primate (NHP) studies that provide support for the new 6 X 10^10 vg/eye (6E10) dose that Adverum intends to include in its next clinical trial. Related: Adverum Bio Posts Additional Efficacy, Safety Data From

  • Simply Wall St.

    How Much Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Do Institutions Own?

    A look at the shareholders of Adverum Biotechnologies, Inc. ( NASDAQ:ADVM ) can tell us which group is most powerful...

  • Benzinga

    Adverum Bio Posts Additional Efficacy, Safety Data From ADVM-022 Gene Therapy In Wet AMD

    Adverum Biotechnologies Inc (NASDAQ: ADVM) announced the presentation of a new post-hoc analysis from the OPTIC study of ADVM-022 in wet age-related macular degeneration (wet AMD). Data were shared at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting. The new data from OPTIC assessed the potential impact of baseline neutralizing antibodies (NAbs) levels on efficacy and safety outcomes with ADVM-022. Related: Adverum Outlines Development Plan For ADVM-022 Gene Th

Advertisement
Advertisement